Jun 2026 (Q2 FY26) — Aug 6, 2026
Outset Medical Q2 FY26 — Strong Console Sales and HCA Refresh Agreement Drive Performance
Read the full callOutset Medical (OM) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Outset Medical earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 31.6 | +0.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -49.5 | +4.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -18.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.08 +6.25% · +$0.24
Performance −69.5% 1Y
1Y: $13.38 on 14 Oct 2025 → $4.08. High $15.53 (20 Oct 2025), low $2.96 (28 Sept 2026).
- Previous close
- $3.84
- 52-week range
- $2.96 – $15.53
- One year
- −69.93%
Overview
- Symbol
- OM
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Outset Medical earnings calls (OM)
Financials
What the filings say
Net profit, year on year: +3% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 29 | 30 | 31 | 29 | 29 | 28 | 32 |
| Operating profit | -24 | -22 | -16 | -17 | -16 | -18 | -17 | -16 |
| Operating margin | −83.2% | −74.2% | −55.1% | −53.7% | −53.7% | −61.0% | −60.7% | −49.5% |
| Other income | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Interest | 6 | 6 | 4 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | -28 | -26 | -26 | -18 | -17 | -19 | -19 | -18 |
| Tax rate | −0.7% | 0.0% | −0.5% | −0.6% | −2.3% | −0.5% | −1.2% | −1.2% |
| Net profit | -28 | -26 | -26 | -19 | -18 | -19 | -19 | -18 |
| EPS ($ per share) | -8.02 | — | -3.66 | -1.04 | -1 | — | -1.03 | -0.97 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -373 | -494 | -626 | -789 | -962 | -1,090 | -1,171 |
| Total liabilities | — | 51 | 75 | 89 | 154 | 191 | 249 | 138 |
| Fixed assets | — | 8 | 15 | 13 | 16 | 13 | 8 | 5 |
| Investments | — | 33 | 20 | 157 | 214 | 135 | 35 | 134 |
| Total assets | — | 88 | 404 | 463 | 400 | 314 | 276 | 264 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -46 | -70 | -99 | -130 | -146 | -131 | -116 | -46 |
| Cash from investing | -69 | 74 | 4 | -143 | -66 | 83 | 104 | -98 |
| Cash from financing | 135 | 0 | 386 | 160 | 73 | 44 | 68 | 56 |
| Net cash flow | 20 | 4 | 291 | -113 | -139 | -5 | 56 | -89 |
| Capital expenditure | -2 | -3 | -9 | -3 | -8 | -3 | -1 | -1 |
| Free cash flow | -48 | -74 | -108 | -133 | -154 | -135 | -117 | -47 |
Insider filings
39 filings between Nov 17, 2025 and Oct 2, 2026.
Open market
decisions to buy or sellPurchases
$870.3K
2 purchases by 1 insider
Sales
$369.2K
23 sales by 5 insiders
Compensation
not trading decisions- 11
- Award — granted as compensation
Also filed: 3 option exercises.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Leonard Braden Michael | $870.3K | — | Oct 2, 2026 |
| Trigg Leslie | — | $122.1K | Aug 17, 2026 |
| Gaeta Renee | — | $107.2K | Aug 17, 2026 |
| Brottem John L. | — | $87.2K | Aug 17, 2026 |
| Nash Marc | — | $45.9K | May 15, 2026 |
| Drexler Karen | — | $6.8K | Dec 1, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Leonard Braden Michael 10% owner | Purchase | 16,575 | $64.2K |
| Oct 1, 2026 | Leonard Braden Michael 10% owner | Purchase | 228,334 | $806.0K |
| Aug 17, 2026 | Brottem John L. General Counsel | Sale | 2,632 | $11.6K |
| Aug 17, 2026 | Trigg Leslie Chair and CEO | Sale | 3,437 | $15.1K |
| Aug 17, 2026 | Gaeta Renee Chief Financial Officer | Sale | 4,543 | $19.9K |
| Jun 26, 2026 | Trigg Leslie Chair and CEO | Award | 99,160 | $0 |
| Jun 26, 2026 | Gaeta Renee Chief Financial Officer | Award | 71,630 | $0 |
| Jun 26, 2026 | Brottem John L. General Counsel | Award | 59,830 | $0 |
| Jun 4, 2026 | Drexler Karen Director | Award | 10,667 | $0 |
| Jun 4, 2026 | LANG BRENT D. Director | Award | 10,667 | $0 |
| Jun 4, 2026 | Prange Karen Director | Award | 10,667 | $0 |
| Jun 4, 2026 | OBOYLE KEVIN C Director | Award | 10,667 | $0 |
| Jun 4, 2026 | HACKETT PATRICK T Director | Award | 10,667 | $0 |
| Jun 4, 2026 | GROSSMAN D KEITH Director | Award | 10,667 | $0 |
| Jun 3, 2026 | Gaeta Renee Chief Financial Officer | Sale | 17,672 | $87.3K |
| May 15, 2026 | Trigg Leslie Chair and CEO | Sale | 3,445 | $12.7K |
| May 15, 2026 | Nash Marc EVP Operations R&D & Service | Sale | 1,582 | $5.9K |
| May 15, 2026 | Brottem John L. General Counsel | Sale | 2,638 | $9.8K |
| May 15, 2026 | Leonard Braden Michael 10% owner | Option exercised | 323,000 | $1.61M |
| May 11, 2026 | Leonard Braden Michael 10% owner | Option exercised | 96,900 | $484.5K |
| May 8, 2026 | Leonard Braden Michael 10% owner | Option exercised | 197,600 | $988.0K |
| Apr 6, 2026 | Elliott Derick A. EVP, Commercial | Award | 96,000 | $0 |
| Feb 17, 2026 | Brottem John L. General Counsel | Sale | 2,842 | $9.5K |
| Feb 17, 2026 | Trigg Leslie Chair and CEO | Sale | 3,361 | $11.3K |
| Feb 17, 2026 | Nash Marc EVP Operations R&D & Service | Sale | 1,817 | $6.1K |
| Jan 21, 2026 | Nash Marc EVP Operations R&D & Service | Sale | 980 | $4.9K |
| Jan 21, 2026 | Trigg Leslie Chair and CEO | Sale | 2,120 | $10.7K |
| Jan 21, 2026 | Brottem John L. General Counsel | Sale | 1,180 | $5.9K |
| Jan 20, 2026 | Nash Marc EVP Operations R&D & Service | Sale | 5,375 | $27.5K |
| Jan 20, 2026 | Brottem John L. General Counsel | Sale | 9,314 | $47.7K |
| Jan 20, 2026 | Trigg Leslie Chair and CEO | Sale | 11,794 | $60.4K |
| Jan 9, 2026 | Prange Karen Director | Award | 18,667 | $0 |
| Jan 7, 2026 | Nash Marc EVP Operations R&D & Service | Sale | 108 | $461 |
| Jan 7, 2026 | Brottem John L. General Counsel | Sale | 224 | $956 |
| Jan 7, 2026 | Trigg Leslie Chair and CEO | Sale | 1,795 | $7.7K |
| Dec 1, 2025 | Drexler Karen Director | Sale | 1,548 | $6.8K |
| Nov 17, 2025 | Trigg Leslie Chair and CEO | Sale | 916 | $4.2K |
| Nov 17, 2025 | Nash Marc EVP Operations R&D & Service | Sale | 247 | $1.1K |
| Nov 17, 2025 | Brottem John L. General Counsel | Sale | 388 | $1.8K |
| Aug 25, 2025 | Nash Marc EVP, R&D, Operations and Serv. | Award | 5,617 | $0 |
| Aug 15, 2025 | Trigg Leslie Chair and CEO | Sale | 904 | $11.6K |
| Aug 15, 2025 | Nash Marc SVP Operations and R&D | Sale | 243 | $3.1K |
| Aug 15, 2025 | Brottem John L. General Counsel | Sale | 383 | $4.9K |
| Jun 10, 2025 | Brottem John L. General Counsel | Award | 35,993 | $0 |
| Jun 10, 2025 | Nash Marc SVP Operations and R&D | Award | 29,676 | $0 |
| Jun 10, 2025 | Gaeta Renee Chief Financial Officer | Award | 131,425 | $0 |
| Jun 10, 2025 | Trigg Leslie Chair and CEO | Award | 65,103 | $0 |
| Jun 2, 2025 | HACKETT PATRICK T Director | Award | 8,983 | $0 |
| Jun 2, 2025 | Drexler Karen Director | Award | 8,983 | $0 |
| Jun 2, 2025 | GROSSMAN D KEITH Director | Award | 8,983 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Outset Medical, Inc.
Free account. Everything above stays public.
Write why you follow Outset Medical, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading